Celiac Disease-Specific TG2-Targeted Autoantibodies Inhibit Angiogenesis Ex Vivo and In Vivo in Mice by Interfering with Endothelial Cell Dynamics

PLoS ONE

Volumn 8, Issue 6, 2013, Pages

  Kalliokoski, Suvi ^a   Sulic, Ana Marija ^a   Korponay Szabó, Ilma R ^a,b   Szondy, Zsuzsa ^b   Frias, Rafael ^c   Perez, Mileidys Alea ^d   Martucciello, Stefania ^a,e   Roivainen, Anne ^f   Pelliniemi, Lauri J ^g   Esposito, Carla ^e   Griffin, Martin ^d   Sblattero, Daniele ^h   Mäki, Markku ^a   Kaukinen, Katri ^a   Lindfors, Katri ^a   Caja, Sergio ^a  

^a TAMPERE UNIVERSITY OF TECHNOLOGY   (Finland)

^b UNIVERSITY OF DEBRECEN   (Hungary)

^c UNIVERSITY OF TURKU   (Finland)

^d ASTON UNIVERSITY   (United Kingdom)

^e UNIVERSITY OF SALERNO   (Italy)

^f TURKU UNIVERSITY HOSPITAL   (Finland)

^g UNIVERSITY OF TURKU   (Finland)

^h UNIVERSITY OF EASTERN PIEDMONT   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

AUTOANTIBODY; FLUORODEOXYGLUCOSE F 18; IMMUNOGLOBULIN A ANTIBODY; PROTEIN GLUTAMINE GAMMA GLUTAMYLTRANSFERASE 2; PROTEIN GLUTAMINE GAMMA GLUTAMYLTRANSFERASE 2 ANTIBODY; UNCLASSIFIED DRUG; GUANINE NUCLEOTIDE BINDING PROTEIN; PROTEIN GLUTAMINE GAMMA GLUTAMYLTRANSFERASE;

ANIMAL TISSUE; ANTIANGIOGENIC ACTIVITY; ARTICLE; CELIAC DISEASE; CELL MOTILITY; CONTROLLED STUDY; ENDOTHELIUM CELL; EX VIVO STUDY; EXTRACELLULAR MATRIX; EXTRACELLULAR SPACE; FEMALE; HUMAN; HUMAN CELL; IN VIVO STUDY; MOUSE; NONHUMAN; POSITRON EMISSION TOMOGRAPHY; ANIMAL; BAGG ALBINO MOUSE; C57BL MOUSE; IMMUNOLOGY; KNOCKOUT MOUSE; NEOVASCULARIZATION (PATHOLOGY); UMBILICAL VEIN ENDOTHELIAL CELL;

MURINAE; MUS;

ANIMALS; AUTOANTIBODIES; CELIAC DISEASE; ENDOTHELIAL CELLS; FEMALE; GTP-BINDING PROTEINS; HUMAN UMBILICAL VEIN ENDOTHELIAL CELLS; HUMANS; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; MICE, KNOCKOUT; NEOVASCULARIZATION, PATHOLOGIC; TRANSGLUTAMINASES;

EID: 84879136370     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0065887     Document Type: Article

References (30)

1. Carmeliet P, (2003) Angiogenesis in health and disease. Nat Med 9: 653-660.
2. Danese S, Sans M, De La Motte C, Graziani C, West G, et al. (2006) Angiogenesis as a novel component of inflammatory bowel disease pathogenesis. Gastroenterology 130: 2060-2073.
3. Alkim C, Sakiz D, Alkim H, Livaoglu A, Kendir T, et al. (2012) Thrombospondin-1 and VEGF in inflammatory bowel disease. The Libyan journal of medicine 7.
4. Myrsky E, Syrjanen M, Korponay-Szabo IR, Maki M, Kaukinen K, et al. (2009) Altered small-bowel mucosal vascular network in untreated coeliac disease. Scand J Gastroenterol 44: 162-167.
5. Cooke WT, Holmes GKT (1984) Coeliac disease. Edinburgh; New York: Churchill Livingstone. 281 p.
6. Dieterich W, Ehnis T, Bauer M, Donner P, Volta U, et al. (1997) Identification of tissue transglutaminase as the autoantigen of celiac disease. Nat Med 3: 797-801.
7. Korponay-Szabo IR, Halttunen T, Szalai Z, Laurila K, Kiraly R, et al. (2004) In vivo targeting of intestinal and extraintestinal transglutaminase 2 by coeliac autoantibodies. Gut 53: 641-648.
8. Lorand L, Graham RM, (2003) Transglutaminases: crosslinking enzymes with pleiotropic functions. Nat Rev Mol Cell Biol 4: 140-156.
9. Jones RA, Kotsakis P, Johnson TS, Chau DY, Ali S, et al. (2006) Matrix changes induced by transglutaminase 2 lead to inhibition of angiogenesis and tumor growth. Cell Death Differ 13: 1442-1453.
10. Myrsky E, Kaukinen K, Syrjanen M, Korponay-Szabo IR, Maki M, et al. (2008) Coeliac disease-specific autoantibodies targeted against transglutaminase 2 disturb angiogenesis. Clin Exp Immunol 152: 111-119.
11. Myrsky E, Caja S, Simon-Vecsei Z, Korponay-Szabo IR, Nadalutti C, et al. (2009) Celiac disease IgA modulates vascular permeability in vitro through the activity of transglutaminase 2 and RhoA. Cell Mol Life Sci 66: 3375-3385.
12. De Laurenzi V, Melino G, (2001) Gene disruption of tissue transglutaminase. Mol Cell Biol 21: 148-155.
13. Marzari R, Sblattero D, Florian F, Tongiorgi E, Not T, et al. (2001) Molecular dissection of the tissue transglutaminase autoantibody response in celiac disease. J Immunol 166: 4170-4176.
14. Simon-Vecsei Z, Kiraly R, Bagossi P, Toth B, Dahlbom I, et al. (2012) A single conformational transglutaminase 2 epitope contributed by three domains is critical for celiac antibody binding and effects. Proc Natl Acad Sci U S A 109: 431-436.
15. Di Niro R, Ziller F, Florian F, Crovella S, Stebel M, et al. (2007) Construction of miniantibodies for the in vivo study of human autoimmune diseases in animal models. BMC Biotechnol 7: 46.
16. Abrámoff MD, Magelhaes PJ, Ram SJ, (2004) Image processing with ImageJ. Biophotonics International 11: 36-42.
17. Norrby K, (2006) In vivo models of angiogenesis. Journal of cellular and molecular medicine 10: 588-612.
18. Malinda KM (2009) In vivo matrigel migration and angiogenesis assay. In: Martin S, Murray JC, editors. Angiogenesis protocols; Methods in molecular biology. 2nd ed. New York; London: Humana; Springer distributor. pp. 287-294.
19. Pagonopoulou O, Efthimiadou A, Lambropoulou M, Papadopoulos N, Nikolettos NK, (2008) Erythropoietin and growth factors exhibit differential angiogenic potential in mouse heart. In vivo 22: 587-591.
20. Ribatti D, Presta M, Vacca A, Ria R, Giuliani R, et al. (1999) Human erythropoietin induces a pro-angiogenic phenotype in cultured endothelial cells and stimulates neovascularization in vivo. Blood 93: 2627-2636.
21. Griffin M, Mongeot A, Collighan R, Saint RE, Jones RA, et al. (2008) Synthesis of potent water-soluble tissue transglutaminase inhibitors. Bioorg Med Chem Lett 18: 5559-5562.
22. Frojdman K, Paranko J, Virtanen I, Pelliniemi LJ, (1992) Intermediate filaments and epithelial differentiation of male rat embryonic gonad. Differentiation 50: 113-123.
23. Smith KA, Hill SA, Begg AC, Denekamp J, (1988) Validation of the fluorescent dye Hoechst 33342 as a vascular space marker in tumours. Br J Cancer 57: 247-253.
24. Nurminskaya MV, Belkin AM, (2012) Cellular functions of tissue transglutaminase. Int Rev Cell Mol Biol 294: 1-97.
25. Caja S, Myrsky E, Korponay-Szabo IR, Nadalutti C, Sulic AM, et al. (2010) Inhibition of transglutaminase 2 enzymatic activity ameliorates the anti-angiogenic effects of coeliac disease autoantibodies. Scand J Gastroenterol 45: 421-427.
26. Guedez L, Stetler-Stevenson WG (2008) Matrix metalloproteinases and their endogenous inhibitors. In: Figg WD, Folkman J, editors. Angiogenesis: an integrative approach from science to medicine. 1st ed. New York: Springer. pp. 55-62.
27. Papetti M, Herman IM, (2002) Mechanisms of normal and tumor-derived angiogenesis. Am J Physiol Cell Physiol 282: C947-970.
28. Rubio-Tapia A, Herman ML, Ludvigsson JF, Kelly DG, Mangan TF, et al. (2012) Severe spruelike enteropathy associated with olmesartan. Mayo Clinic proceedings Mayo Clinic 87: 732-738.
29. Cheng XW, Song H, Sasaki T, Hu L, Inoue A, et al. (2011) Angiotensin type 1 receptor blocker reduces intimal neovascularization and plaque growth in apolipoprotein E-deficient mice. Hypertension 57: 981-989.
30. Abadie V, Sollid LM, Barreiro LB, Jabri B, (2011) Integration of genetic and immunological insights into a model of celiac disease pathogenesis. Annual review of immunology 29: 493-525.